Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for
treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic …

PURPOSE Tisagenlecleucel is a CD19-specific chimeric antigen receptor T-cell therapy,
US Food and Drug Administration–approved for children, adolescents, and young adults (CAYA…

Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic
malignancies. However, treatment failure after initial response approaches 50%. In allogeneic …

Remarkable complete response rates have been shown with tisagenlecleucel, a chimeric
antigen receptor (CAR) T-cell therapy targeting CD19, in patients up to age 26 years with …

Background: CTL019 is an investigational therapy derived from autologous T-cells expressing
a CD19-specific chimeric antigen receptor (CAR). A single center, phase I/IIa trial of …

Down syndrome-associated acute lymphoblastic leukemia (DS-ALL) patients suffer risk of
chemotherapy-associated toxicities and poor outcomes. We evaluated tisagenlecleucel in 16 …

… John E Levine, 1, 2 Stephan A Grupp, 3, 4 Michael A Pulsipher, 5 Andrew C Dietz, 5
Susana Rives, 6, 7 G Douglas Myers, 8 Keith J August, 8 Michael R Verneris, 9, 10 Jochen …

Allogeneic hematopoietic cell transplantation (HCT) is indicated for patients with relapsed
or refractory B acute lymphoblastic leukemia (B-ALL), where outcomes remain poor with …

Chimeric antigen receptor (CAR) T cells have transformed the therapeutic options for
relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia. Data for CAR therapy in …

Introduction: Chimeric Antigen Receptor (CAR) T cell therapy targeting CD19 has shifted
our treatment approach for relapsed and refractory (r/r) pediatric B cell acute lymphoblastic …